Healthcare >> Analyst Interviews >> April 21, 2017

Health Care Uncertainty Not Reflected in Med Tech Valuations

Suraj Kalia, CFA, is a Managing Director and Senior Research Analyst at Northland Capital Markets. Mr. Kalia has over 15 years of experience working in the health care and financial industries. His prior experience includes acting as Senior Medical Device Analyst at Rodman & Renshaw, Piper Jaffray and Northland Capital Markets. Mr. Kalia was twice ranked as a top-five Medical Device Analyst in The Wall Street Journal’s “Best on the Street” survey. He is viewed as one of the most respected and authoritative voices in medical device equity research. Mr. Kalia completed his bachelor’s degree in chemical engineering from the Indian Institute of Technology, Bombay, India; master’s degree in chemical engineering at Stevens Institute of Technology in Hoboken, New Jersey, and his MBA from the University of St. Thomas in St. Paul, Minnesota. He holds and maintains the FINRA Series 7 General Securities Representative, Series 63 Uniform Securities Agent State Law, and Series 87 Research Analyst registrations. Mr. Kalia currently sits on the board of directors of NeuroOne, Inc. Profile
TWST: Can you give us a sense of what your coverage is?

Mr. Kalia: I cover cardiovascular, neuro, drug delivery and various therapeutic segments such as peripheral

Pin It on Pinterest

Share This